Log In

Reset Password

New CCO brings global expertise to Rua Bioscience

Rua Bioscience has appointed experienced global pharmaceutical executive Dr Andrea Grant as its chief commercial officer (CCO).

Dr Grant will drive the medicinal cannabis company's domestic and global commercialisation and business development strategy. Dr Grant's first priority will be to lead Rua's global expansion into key markets.

She brings 20 years of business development experience in the pharmaceutical and biotech industries globally. Dr Grant comes to Rua from Janssen Cilag Pty NZ (the pharmaceutical business of Johnson & Johnson), where she was the market access manager responsible for commercialising innovative medicines to New Zealand patients.

Her global experience in biotech includes senior business development roles at Incyte and Galapagos, both during their early stages of transitioning to fully integrated pharmaceutical companies, as well as management director of Living Cell Technologies.

Dr Grant will also add value to Rua's global commercial discipline, her experience garnered from working with pharmaceutical stalwarts like Janssen and Roche.

“Andi is an exciting hire for the company as we prepare to enter both the German and domestic markets and develop our IP strategy across the medicinal cannabis value chain,” said Rua Bioscience CEO Rob Mitchell.

The first market is Germany, where Rua holds an exclusive distribution agreement with Nimbus Health.

“Andi has carved out an outstanding international career focused on the commercialisation of medical innovations in the pharmaceutical and biotech sectors across the UK, Europe, US, New Zealand and Asia.

“She's a proven value creator, skilled negotiator and vastly experienced leader who knows how to bring novel products to market. She is also a great fit for Rua's unique vision and kaupapa,” he says.

Dr Grant says she's thrilled to join Rua Bioscience.

“Rua's long-term vision to become a fully integrated pharmaceutical company is eminently achievable, especially given the company's laser focus on driving revenue that we can reinvest on securing IP,” she says.

Rua's kaupapa is something that resonates strongly with Dr Grant.

“Rua's social vision is well aligned with my own principles both personally and professionally, Dr Grant holds a PhD in molecular neurobiology from the University of Cambridge, UK. She is a proud parent of two sons and two daughters, and is a keen sportswoman, particularly enjoying sea swimming, mountain and road biking.

Dr Grant takes up her position with Rua Bioscience on June 7 2021.

Dr Andrea Grant